Pharmacokinetic Study of Nilotinib in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor Showing Failure to Both Imatinib and Sunitinib.

Trial Profile

Pharmacokinetic Study of Nilotinib in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor Showing Failure to Both Imatinib and Sunitinib.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2013

At a glance

  • Drugs Nilotinib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Pharmacokinetics
  • Most Recent Events

    • 16 Jul 2012 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.
    • 28 Sep 2011 Planned end date changed from 1 Dec 2010 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 29 Jul 2010 Planned end date changed from Jun 2010 to Dec 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top